F. Grange, ??pid??miologie du m??lanome cutan?? : donn??es descriptives en France et en Europe, Annales de Dermatologie et de V??n??r??ologie, vol.132, issue.12
DOI : 10.1016/S0151-9638(05)79560-0

. Europe and . In, Annales de Dermatologie et de Vénéréologie, Internet], pp.975-982, 2005.

. Disponible-sur, Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy):25264. 3. Ribas A, others. Tumor immunotherapy directed at PD-1, Nat Rev Cancer. 22 mars N Engl J Med, vol.12366, issue.2426, pp.2517-2519, 2012.

F. Hodi, O. Day, S. Mcdermott, D. Weber, R. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.2010711-723, 2010.
DOI : 10.1056/NEJMoa1003466

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549297/pdf

C. Mateus, C. Libenciuc, and C. Robert, Place des anti-PD1 dans la prise en charge des m??lanomes cutan??s, Bulletin du Cancer, vol.103, issue.6, pp.4-11, 2016.
DOI : 10.1016/S0007-4551(16)30140-0

T. Lambert, L. Doucet, A. Gupta, D. Felice, K. Loftus et al., Systematic review: colitis associated with anti-CTLA-4 therapy Colite induite par les inhibiteurs de checkpoint immunitaire : anticorps anti-CTLA-4 et anticorps anti-PD-1/PDL-1 Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung c ancer, Immunothérapie et dysfonctions thyroïdiennes : mise au point sur les connaissances actuelles, pp.50915-115018, 2015.

E. Blin and S. Marchand-adam, Les nouvelles pneumopathies interstitielles li??es aux th??rapies cibl??es et immunoth??rapies, Revue des Maladies Respiratoires Actualit??s, vol.8, issue.2, pp.170-172, 2016.
DOI : 10.1016/S1877-1203(16)30084-2

P. Bogaerts, J. Schwartz, L. Sargent, D. Ford, and R. , New Guidelines to Evaluate the Response to Treatment in Solid Tumors New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), J Natl Cancer Inst. 2 févr Eur J Cancer. janv, vol.9245, issue.32, p.22847, 2000.

D. Giacomo, A. Danielli, R. Guidoboni, M. Calabrò, L. Carlucci et al., Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases, Cancer Immunology, Immunotherapy, vol.12, issue.8, p.1297306, 2009.
DOI : 10.1016/S1359-6349(07)71459-3

F. Hodi, M. Butler, D. Oble, M. Seiden, F. Haluska et al., Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients A clinical development paradigm for cancer vaccines and related biologics, Proc Natl Acad Sci. J Immunother, vol.10530, issue.81, pp.3005-30101, 2007.

F. Hodi, W. Hwu, R. Kefford, J. Weber, A. Daud et al., Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab Interobserver and Intraobserver Variability in Measurement of Non?Small-Cell Carcinoma Lung Lesions: Implications for Assessment of Tumor Response CT Tumor Volume Measurement in Advanced Non-small-cell Lung Cancer Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements, Chiou VL, Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors, pp.15107-22393643, 2003.
DOI : 10.1200/jco.2015.64.0391

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070547/pdf

L. Lay, J. Jarraya, H. Lebellec, L. Penel, N. Seymour et al., IrRECIST and iRECIST: the devil is in the details Ferté C, Marabelle A. iRECIST: A clarification of tumour response assessment in the immunotherapy era iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Ann Oncol Off J Eur Soc Med Oncol. 5 avr Eur J Cancer. mai Lancet Oncol, vol.287718, issue.293, pp.1657-143, 2017.

L. Disponible-sur-khoja, M. Kibiro, U. Metser, C. Gedye, D. Hogg et al., Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab, Br J Cancer. 8 nov JAMA Dermatol. 1 janv N Engl J Med, vol.1523115152, issue.34366, pp.118692-334520122455, 2012.

O. Hamid, C. Robert, A. Daud, F. Hodi, W. Hwu et al., Safety and Tumor Responses with Lambrolizumab (Anti?PD-1) in Melanoma Phase I Study of Single-Agent Anti?Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, N Engl J Med. 11 juill J Clin Oncol. juill Nature. 26 nov, vol.36928515, issue.2197528, pp.13444-36316775, 2010.